Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verucerfont. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 known ✓ | P34998 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verucerfont SCHEMBL1237818 | 1.00 | CRHR1 (1.00) | CRHR1 | |
| Verucerfont SCHEMBL1236701 | 1.00 | CRHR1 (1.00) | CRHR1 | |
| Verucerfont SCHEMBL29482259 | 1.00 | CRHR1 (1.00) | CRHR1 | |
| Verucerfont SCHEMBL18407291 | 0.94 | CRHR1 (0.89) | CRHR1 | |
| SCHEMBL1236383 | 0.93 | CRHR1 (0.87) | CRHR1 | |
| SCHEMBL1237278 | 0.93 | CRHR1 (0.87) | CRHR1 | |
| SCHEMBL1237475 | 0.92 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL1236362 | 0.92 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL1236641 | 0.92 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL1237774 | 0.92 | CRHR1 (0.84) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-06-05 | — | — | US | claimed |
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-03-27 | — | — | US | claimed |
| EP-4479404-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | Awakn Ls Europe Holdings Limited (IE) | 2024-12-25 | — | — | EP | claimed |
| EP-4450070-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-23 | — | — | EP | claimed |
| US-20240190809-A1 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2024-06-13 | — | — | US | claimed |
| EP-4337316-A1 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | Awakn Ls Europe Holdings Limited (IE) | 2024-03-20 | — | — | EP | claimed |
| WO-2023156565-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2023-08-24 | — | — | WO | claimed |
| WO-2023139163-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2023-07-27 | — | — | WO | claimed |
| WO-2022150525-A9 | MDMA IN THE TREATMENT OF ALCOHOL USE DISORDER | AWAKN LIFE SCIENCES INC. (CA) | 2023-04-20 | — | — | WO | claimed |
| US-20220395486-A1 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-15 | — | — | US | claimed |
| US-20170020877-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. | 2017-01-26 | — | — | US | claimed |
| EP-3096756-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-11-30 | — | — | EP | claimed |
| WO-2015112642-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2015-07-30 | — | — | WO | claimed |
| EP-1802627-B1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2012-08-29 | — | — | EP | claimed |
| EP-1934222-B1 | Pyrazolo[1, 5 -alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists | SMITHKLINE BEECHAM CORK LTD (IE) | 2012-07-25 | — | — | EP | claimed |
| US-8088779-B2 | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2012-01-03 | — | — | US | claimed |
| US-20080306092-A1 | Pyrazolo [1,5-Alpha] Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | SB PHARMCO PUERTO RICO INC. (US) | 2008-12-11 | — | — | US | claimed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | claimed |
| EP-1802627-A1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044958-A1 | PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | DBH, TSPO, DDO | CRHR1 447/4885 |
| US-20240190809-A1 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | AADAT, PNMT, SLC1A2 | CRHR1 175/4885 |
| US-20170020877-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | CRHR1, MC2R, CRH | CRHR1 1/4885 |
| US-20080306092-A1 | Pyrazolo [1,5-Alpha] Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | PNMT, SLC18A2, HTR2C | CRHR1 234/4885 |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.